This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eichhorn, P. J.A. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Eichhorn, P. J.A. Articles by Baselga, J.

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

¹ Medical Oncology Program, Vall d Hebron Institut de Oncologia, Barcelona, Spain; ² Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands; ³ Autonomous University of Barcelona, Barcelona; and ⁴ Instituci Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Requests for reprints: José Baselga, Vall d'Hebron University Hospital, P. Vall d'Hebron 119, Barcelona, 08035 Spain. Phone: 01134-932746085; Fax: 01134-932746059; E-mail: jbaselga{at}vhebron.net.

Key Words: breast cancer • lapatinib • barcode screen • PI3K pathway • PI3K inhibitors

Small molecule inhibitors of HER2 are clinically active in women with advanced HER2-positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approach, we performed a genome wide loss-of-function short hairpin RNA screen to identify novel modulators of resistance to lapatinib, a recently approved anti-HER2 tyrosine kinase inhibitor. Here, we have identified the tumor suppressor PTEN as a modulator of lapatinib sensitivity in vitro and in vivo. In addition, we show that two dominant activating mutations in PIK3CA (E545K and H1047R), which are prevalent in breast cancer, also confer resistance to lapatinib. Furthermore, we show that phosphatidylinositol 3-kinase (PI3K)–induced lapatinib resistance can be abrogated through the use of NVP-BEZ235, a dual inhibitor of PI3K/mTOR. Our data show that deregulation of the PI3K pathway, either through loss-of-function mutations in PTEN or dominant activating mutations in PIK3CA, leads to lapatinib resistance, which can be effectively reversed by NVP-BEZ235. [Cancer Res 2008;68(22):9221–30]

This article has been cited by other articles:

				G. Konstantinidou, E. A. Bey, A. Rabellino, K. Schuster, M. S. Maira, A. F. Gazdar, A. Amici, D. A. Boothman, and P. P. Scaglioni Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non-Small Cell Lung Cancer Harboring K-RAS Mutations Cancer Res., October 1, 2009; 69(19): 7644 - 7652. [Abstract] [Full Text] [PDF]

				B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga Status of PI3K inhibition and biomarker development in cancer therapeutics Ann. Onc., August 27, 2009; (2009) mdp347v1. [Abstract] [Full Text] [PDF]

				D. Faratian, A. Goltsov, G. Lebedeva, A. Sorokin, S. Moodie, P. Mullen, C. Kay, I. H. Um, S. Langdon, I. Goryanin, et al. Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab Cancer Res., August 15, 2009; 69(16): 6713 - 6720. [Abstract] [Full Text] [PDF]

				S. Di Cosimo and J. Baselga Phosphoinositide 3-Kinase Mutations in Breast Cancer: A "Good" Activating Mutation? Clin. Cancer Res., August 15, 2009; 15(16): 5017 - 5019. [Abstract] [Full Text] [PDF]

				Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines Ann. Onc., July 24, 2009; (2009) mdp304v1. [Abstract] [Full Text] [PDF]